Skip to main content

Table 1 Patient characteristics and clinical outcomes

From: Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma

Patient

Sex

Age

Stage

Site of metastasis

Previous therapies (drug)

Enrolled

Vaccine treatment

OR

TTP (months)

Overall survival (months)

1

F

71

IIIC

Skin recurrence

None

Yes

Complete

SD

7

34

2

F

47

IV

Lung, lymphonodal

2 (DTIC, Vemurafenib)

Yes

2 injections

PD

2

2

3

M

73

IV

Skin lymphnodal, liver

3 (DTIC, Vemurafenib, Ipilimumab)

Yes

Complete

SD

26

31

4

M

38

IV

Lymphonodal, lung

1(Vemurafenib)

Yes

2 injections

PD

2

5

5

M

66

IV

Lung, lymphonodal

3 (DTIC-IL2, BOLD, Ipilimumab)

Yes

Complete

SD

5

9

6

F

68

IV

Skin, lung, lymphonodal

2 (DTIC, Ipilimumab

Yes

No injection

NA

NA

NA

7

F

63

IV

Adrenal, lymphonodal

none

No

8

M

69

IV

Brain, lymphonodal, lung, bone

3(Fotemustine, Ipilimumab, DTIC)

No

9

F

51

IV

Brain, lung, lymphonodal, spleen

5 (DTIC, Fotemustine, Paclitaxel, Ipilimumab, Dabrafenib

No

10

M

66

IV

Lung, lymphonodal, spleen

4 (DTIC+ Bevacizumab, Fotemustine, CDDP + Paclitaxel, Ipilimumab)

No